TOKYO, Apr 28 (Pulse News Wire) – NEOPT Inc. (311A.T), led by CEO Kenichiro Harada, plans to delist its shares from the TOKYO PRO Market.
A special shareholders' meeting scheduled for June 30, 2026 will vote on the proposal. Following shareholder approval, the company expects to complete the delisting process by July 30, 2026. The decision stems from limited liquidity post-IPO and the need for more flexible funding options to support ongoing clinical trials and accelerate business growth.
NEOPT believes non-listed status will allow for quicker fundraising activities and strengthen internal management systems for future general market listing. Key milestones include setting the record date for voting rights on May 15, 2026, electronic notification of the meeting on April 30, 2026, physical mail-out of notices on June 06, 2026, and submission of the delisting application to the Tokyo Stock Exchange on June 15, 2026. The final delisting date is set for July 30, 2026.
NEOPT remains committed to advancing personalized medicine through its innovative cancer treatments, such as NPT001-HTY, which is currently undergoing Phase I/II clinical trials for esophageal cancer.
🟡 Confidence: Standard AI-translated content.